More Articles

Need for global development programme for biosimilars Conferences | Posted 04/05/2012

There is now a crucial need for a framework that allows global biosimilars development.

Turkish guidelines for generics Guidelines | Posted 04/05/2012

Last update: 4 May 2012 The regulatory body for approval of pharmaceutical products in Turkey is the General Directorate of Pharmaceuticals and Pharmacy (GDPP).

Global generics markets predicted to grow to US$221 billion by 2016 Reports | Posted 04/05/2012

The global markets for generic drugs will continue to grow despite cost reduction measures from governments and healthcare payers in many markets.

Oncologists inconsistent in how they judge value of high-cost cancer drugs Reports | Posted 27/04/2012

A survey of oncologists in Canada and the US has shown that physicians are inconsistent when deciding how long an expensive new cancer therapy should extend a person’s life before the cost of the t...

Amgen buys Turkish generics manufacturer Generics/News | Posted 27/04/2012

US biotechnology giant Amgen announced on 25 April 2012 that the company will pay US$700 million to gain a majority share (95.6%) in Turkish generics company Mustafa Nevzat Pharmaceuticals (MN).

EMA reviews its first biosimilar monoclonal antibody Biosimilars/News | Posted 27/04/2012

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use released in April 2012 the agency will be reviewing a new appl...

Watson now third largest generics company with Actavis acquisition Generics/News | Posted 27/04/2012

Watson Pharmaceuticals (Watson) has confirmed a definitive agreement to acquire privately-owned generics firm Actavis for an upfront payment of Euros 4.25 billion. The acquisition of Actavis makes...

Study of biosimilar enoxaparins in Brazil Biosimilars/Research | Posted 27/04/2012

Analysis of biosimilar enoxaparins available for clinical use in Brazil by the Laboratório de Tecido Conjuntivo in Brazil have shown that the biosimilar preparations of enoxaprain are similar to th...